Melanoma metastatic to the appendix is extremely rare. Here we describe a case of a 31-year-old female from Bolivia with a remote history of metastatic malignant melanoma first diagnosed as a cutaneous malignant melanoma ten years prior to this presentation. The patient was being followed for a mucocele which on resection was found to be metastatic melanoma. "Mucocele" is a generic diagnosis that warrants further characterization and treatment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3087427 | PMC |
| http://dx.doi.org/10.1155/2011/546570 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Tirbanibulin in actinic keratosis treatment: evaluation of effectiveness, safety and patients' satisfaction in a comparison with cryotherapy.
J Dtsch Dermatol Ges
January 2025
Dermatology Unit, University of Pisa, Pisa, Italy.
The Role of AIM2 in Cancer Development: Inflammasomes and Beyond.
J Cancer
January 2025
Center for Immunology, Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases, Ministry of Education, Gannan Medical University, Ganzhou, Jiangxi 341000, China.
Absence in melanoma 2 (AIM2) protein functions as a double-stranded DNA sensor and is critical for host defense against intracellular bacterial and viral pathogens. Recent research has highlighted the significance of AIM2 in the pathogenesis of diverse malignancies. Through its recognition of foreign or intracellular dsDNA, AIM2 triggers inflammasome activation, resulting in the release of pro-inflammatory cytokines such as IL-1β, IL-18, and induction of pyroptosis.
View Article and Find Full Text PDFMelanoma toolkit for early detection for primary care clinicians: a 1-year follow-up on outcomes.
Front Med (Lausanne)
December 2024
Department of Dermatology, Oregon Health & Science University, Portland, OR, United States.
Introduction: Primary care providers or clinicians (PCPs) have the potential to assist dermatologists in screening patients at risk for skin cancer, but require training to appropriately identify higher-risk patients, perform skin checks, recognize and biopsy concerning lesions, interpret pathology results, document the exam, and bill for the service. Very few validated dermatology training programs exist for PCPs and those that are available focus primarily on one emphasis area, which results in variable efficacy and single-topic limited scope.
Methods: We have created a free, online, continuing education program (Melanoma Toolkit for Early Detection, MTED) that allows learners to choose from a variety of multimedia tools (image recognition, videos, written material, in-person seminars, self-tests, etc.
A novel EMT-related risk score model for Uveal melanoma based on ZNF667-AS1 and AP005121.1.
J Cancer
January 2025
Department of Ophthalmology, Southwest Hospital, The Third Military Medical University (Army Medical University), Chongqing, P.R. China.
Uveal melanoma (UM) has emerged as one of the most common primary intraocular malignant tumors worldwide. Long non-coding RNAs (lncRNAs) are increasingly recognized as decisive factors in the progression and metastasis of UM, involving in epithelial-mesenchymal transition (EMT) of UM. We conducted a comprehensive analysis of lncRNAs closely associated with EMT-related genes in the TCGA UM cohort, identifying 961 EMT-related lncRNAs.
View Article and Find Full Text PDFLentinan inhibits melanoma development by regulating the AKT/Nur77/Bcl-2 signaling axis.
J Cancer
January 2025
Engineering Technological Center of Mushroom Industry, Minnan Normal University, Zhangzhou, Fujian 363000, People's Republic of China.
Melanoma is a highly malignant and difficult-to-treat skin cancer. Many researchers are exploring natural products for its treatment. Lentinan (LNT), extracted from , exerts strong anti-tumor effects.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!